Luigi Bolondi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11635736/publications.pdf

Version: 2024-02-01

85 papers	25,123 citations	57758 44 h-index	53230 85 g-index
86 all docs	86 docs citations	86 times ranked	23010 citing authors

#	Article	IF	Citations
1	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open, 2020, 5, e000714.	4.5	51
2	MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Research, 2020, 80, 1720-1734.	0.9	47
3	Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification. Scientific Reports, 2019, 9, 14749.	3.3	9
4	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2019, 8, 171.	2.4	37
5	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treatment Reviews, 2019, 72, 28-36.	7.7	342
6	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Digestive and Liver Disease, 2019, 51, 681-688.	0.9	49
7	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncology, The, 2018, 19, 682-693.	10.7	285
8	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. Acta Histochemica, 2018, 120, 95-102.	1.8	22
9	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death and Disease, 2018, 9, 4.	6.3	68
10	From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. Histopathology, 2018, 72, 414-422.	2.9	13
11	LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget, 2018, 9, 35085-35099.	1.8	46
12	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget, 2018, 9, 15350-15364.	1.8	79
13	DAAs for HCV and risk of hepatocellular carcinoma: current standpoint. The Lancet Gastroenterology and Hepatology, 2018, 3, 736-738.	8.1	6
14	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine, 2018, 379, 54-63.	27.0	1,677
15	Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. Lancet Oncology, The, 2017, 18, e101-e112.	10.7	123
16	Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. Scientific Reports, 2017, 7, 44685.	3.3	11
17	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology, 2017, 67, 173-183.	3.7	165
18	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. Liver Cancer, 2017, 6, 337-348.	7.7	18

#	Article	IF	Citations
19	miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. Digestive Diseases and Sciences, 2017, 62, 2397-2407.	2.3	13
20	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. Hepatic Oncology, 2017, 4, 129-137.	4.2	16
21	TP53/MicroRNA Interplay in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2016, 17, 2029.	4.1	26
22	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepatic Oncology, 2016, 3, 119-136.	4.2	14
23	Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. Journal of Hepatology, 2016, 65, 727-733.	3.7	768
24	Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therapeutic Advances in Gastroenterology, 2016, 9, 240-249.	3.2	70
25	Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis. Internal and Emergency Medicine, 2016, 11, 19-30.	2.0	11
26	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 2016, 7, 31361-31371.	1.8	45
27	Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. Oncotarget, 2016, 7, 39609-39626.	1.8	25
28	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. PLoS ONE, 2015, 10, e0141448.	2.5	113
29	Contrast-enhanced ultrasound in liver cancer. Hepatic Oncology, 2015, 2, 51-62.	4.2	6
30	Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. Molecular Imaging and Biology, 2015, 17, 29-37.	2.6	48
31	Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Digestive and Liver Disease, 2015, 47, 518-522.	0.9	63
32	Refining sorafenib therapy: lessons from clinical practice. Future Oncology, 2015, 11, 449-465.	2.4	17
33	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2015, 16, 1344-1354.	10.7	809
34	Yttriumâ€90 radioembolization vs sorafenib for intermediateâ€locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver International, 2015, 35, 1036-1047.	3.9	94
35	p53/mdm2 Feedback Loop Sustains miR-221 Expression and Dictates the Response to Anticancer Treatments in Hepatocellular Carcinoma. Molecular Cancer Research, 2014, 12, 203-216.	3.4	43
36	State of the art: hepatocellular carcinoma. Future Oncology, 2014, 10, 1-6.	2.4	31

#	Article	IF	Citations
37	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICEâ€1 study. International Journal of Cancer, 2014, 135, 1247-1256.	5.1	109
38	TACE performed in patients with a single nodule of Hepatocellular Carcinoma. BMC Cancer, 2014, 14, 601.	2.6	36
39	Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma. BMC Cancer, 2014, 14, 403.	2.6	7
40	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group. Digestive and Liver Disease, 2014, 46, 549-555.	0.9	57
41	Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. Oncotarget, 2014, 5, 10607-10620.	1.8	39
42	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. European Journal of Cancer, 2013, 49, 3412-3419.	2.8	218
43	Treatment of hepatocellular carcinoma in Child-Pugh B patients. Digestive and Liver Disease, 2013, 45, 852-858.	0.9	32
44	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 712-723.	0.9	155
45	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. Seminars in Liver Disease, 2013, 32, 348-359.	3.6	508
46	Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3Î² phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget, 2013, 4, 1618-1631.	1.8	42
47	Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients. Clinical Cancer Research, 2012, 18, 4397-4405.	7.0	87
48	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. Journal of Hepatology, 2012, 57, 821-829.	3.7	736
49	In hepatocellular carcinoma miRâ€519d is upâ€regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. Journal of Pathology, 2012, 227, 275-285.	4.5	180
50	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology, 2012, 56, 1025-1033.	7.3	150
51	Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. European Journal of Medicinal Chemistry, 2012, 48, 391-401.	5.5	29
52	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, 1015-1021.	0.9	10
53	From liver cirrhosis to HCC. Internal and Emergency Medicine, 2011, 6, 93-98.	2.0	25
54	Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (â‰2Âcm) HCC in cirrhosis. European Radiology, 2011, 21, 1233-1242.	4.5	174

#	Article	IF	Citations
55	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2010, 22, 391-398.	1.6	60
56	Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transplantation, 2010, 16, 658-667.	2.4	93
57	Characterization of Focal Liver Lesions with Contrast-Enhanced Ultrasound. Ultrasound in Medicine and Biology, 2010, 36, 531-550.	1.5	102
58	Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine. Tumori, 2010, 96, 1028-1030.	1.1	11
59	Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1319-1326.	2.3	20
60	MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. Cancer Research, 2010, 70, 5184-5193.	0.9	389
61	Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, 729-734.	0.9	12
62	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. Digestive and Liver Disease, 2010, 42, S258-S263.	0.9	51
63	The Impact of Vascular and Nonvascular Findings on the Noninvasive Diagnosis of Small Hepatocellular Carcinoma Based on the EASL and AASLD Criteria. American Journal of Gastroenterology, 2010, 105, 599-609.	0.4	185
64	MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality. Clinical Cancer Research, 2009, 15, 5073-5081.	7.0	298
65	MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. Cancer Research, 2009, 69, 5761-5767.	0.9	380
66	MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009021.	1.3	3
67	MicroRNA involvement in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2008, 12, 2189-2204.	3.6	248
68	Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 378-390.	27.0	12,004
69	Hepatocellular carcinoma: Epidemiology and clinical aspects. Molecular Aspects of Medicine, 2008, 29, 130-143.	6.4	92
70	Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2008, 48, 848-857.	3.7	113
71	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. Cancer Research, 2007, 67, 6092-6099.	0.9	782
72	Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer, 2007, 7, 171.	2.6	64

#	Article	IF	Citations
73	Recent advances in the diagnosis of hepatocellular carcinoma. Hepatology Research, 2007, 37, S178-92.	3.4	18
74	The safety of SonovueÂ® in abdominal applications: Retrospective analysis of 23188 investigations. Ultrasound in Medicine and Biology, 2006, 32, 1369-1375.	1.5	654
75	Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma. Hepatology, 2005, 42, 27-34.	7.3	410
76	Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. Journal of Hepatology, 2005, 43, 310-316.	3.7	44
77	Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. Journal of Hepatology, 2004, 41, 421-426.	3.7	122
78	Liver metastases from rectal carcinoma: Disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy. Journal of Clinical Ultrasound, 2003, 31, 387-391.	0.8	15
79	Screening for hepatocellular carcinoma in cirrhosis. Journal of Hepatology, 2003, 39, 1076-1084.	3.7	196
80	Assessment of Vascular Patterns of Small Liver Mass Lesions: Value and Limitation of The Different Doppler Ultrasound Modalities. American Journal of Gastroenterology, 2000, 95, 3537-3546.	0.4	45
81	In hepatocellular carcinoma AgNOR protein expression correlates with tumour mass doubling time. Journal of Hepatology, 1996, 24, 60-65.	3.7	19
82	Enzymatic cytochemistry, DNA ploidy and AgNOR quantitation in hepatocellular nodules of uncertain malignant potential in liver cirrhosis. Digestive Diseases and Sciences, 1996, 41, 800-808.	2.3	8
83	Diagnostic and prognostic value of dna ploidy and cell nuclearity in ultrasound-guided liver biopsies. Cancer, 1994, 74, 1713-1719.	4.1	20
84	Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology, 1992, 16, 132-137.	7.3	410
85	Percutaneous etharrol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer, 1992, 69, 925-929.	4.1	401